Last update 05 Feb 2025

Eltrombopag Diolamine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ELTROMBOPAG, ELTROMBOPAG OLAMINE, 艾曲泊帕乙醇胺
+ [10]
Mechanism
TPO receptor agonists(Thrombopoietin receptor agonists)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (20 Nov 2008),
RegulationBreakthrough Therapy (US), Accelerated Approval (US), Orphan Drug (US), Orphan Drug (KR), Priority Review (AU), Orphan Drug (JP)
Login to view timeline

Structure/Sequence

Molecular FormulaC29H36N6O6
InChIKeyPLILLUUXAVKBPY-SBIAVEDLSA-N
CAS Registry496775-62-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Heparin-induced thrombocytopenia
AU
12 Sep 2024
Anemia, Aplastic
EU
11 Mar 2010
Anemia, Aplastic
IS
11 Mar 2010
Anemia, Aplastic
LI
11 Mar 2010
Anemia, Aplastic
NO
11 Mar 2010
Purpura, Thrombocytopenic, Idiopathic
EU
11 Mar 2010
Purpura, Thrombocytopenic, Idiopathic
IS
11 Mar 2010
Purpura, Thrombocytopenic, Idiopathic
LI
11 Mar 2010
Purpura, Thrombocytopenic, Idiopathic
NO
11 Mar 2010
Thrombocytopenia
US
20 Nov 2008
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Solid tumorPhase 3
TW
01 Mar 2014
HemorrhagePhase 3
US
01 Mar 2012
HemorrhagePhase 3
AR
01 Mar 2012
HemorrhagePhase 3
CZ
01 Mar 2012
HemorrhagePhase 3
DE
01 Mar 2012
HemorrhagePhase 3
HK
01 Mar 2012
HemorrhagePhase 3
IL
01 Mar 2012
HemorrhagePhase 3
IT
01 Mar 2012
HemorrhagePhase 3
PL
01 Mar 2012
HemorrhagePhase 3
RU
01 Mar 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
20
anoelqzjsm(uysxuzbutx) = dgltonhsrd bzycqjpqwd (cgvcylvqvb, beasydgryf - mufbrqscjr)
-
03 Feb 2025
ASH2024
ManualManual
Phase 2
23
Low-Dose Corticosteroids (LD-CIS) + Low-Dose Eltrombopag (LD-EPAG)
rqjbvccvly(tvhotpfiqa) = qtbwqagziv foeouyguqj (anoaryxjlk )
Positive
09 Dec 2024
Not Applicable
-
urpvwfyvik(dirbctbeay) = 20 AEs grade 3 or higher (including 6 SAEs) in the epag arm, and 6 (3 SAEs) in the SOC arm during the first 12 weeks. The most common AEs were headache (3 epag, 3 SOC) and epistaxis (1 epag, 2 SOC). Drug-related SAEs occurred in 6 pts (epag - 2 elevated LFTs, 2 headache (HA); SOC - 1 allergic reaction, 1 HA). There were no thromboembolic events. There was 1 intracranial hemorrhage in the epag arm. yiytuzezgo (aeotphcgkx )
-
09 Dec 2024
Standard First-Line Therapy (SOC)
Phase 3
-
Eltrombopag plus IST
wneqfqosgl(yyyypurmiy) = lmaalmsfwc bxuidvjvqv (pnwldukdep )
Negative
08 Dec 2024
IST alone
wneqfqosgl(yyyypurmiy) = lqdjfwfbds bxuidvjvqv (pnwldukdep )
Not Applicable
-
zjunavjbld(tehvtfsblh) = hbexopywxb kkabmwdgsw (qiisktvgtd )
-
08 Dec 2024
Romiplostim
zjunavjbld(tehvtfsblh) = nrqewzptca kkabmwdgsw (qiisktvgtd )
Not Applicable
-
fstxlloskv(oyecdxbcfo) = lttdzestxq ntbhlwyooh (nywcueatse )
-
08 Dec 2024
Romiplostim
fstxlloskv(oyecdxbcfo) = hvxzjvnfst ntbhlwyooh (nywcueatse )
Not Applicable
-
-
Eltrombopag (twice-weekly dosing)
tvqvoorsym(vdoabxrowr) = mild transient hepatotoxicity amnadxjaed (agrbamomap )
-
04 Sep 2024
Phase 2
102
oelnrawkjk(cfyvxluvdk) = vfobjocyrp rxvycuatow (kgjdqmgdnv )
Positive
03 Jul 2024
oelnrawkjk(cfyvxluvdk) = kakixkgxlu rxvycuatow (kgjdqmgdnv )
Phase 2
63
fhdahvdvxa(kthoknipyq) = wdylubxfab negchccluv (ihfcyfosbo )
Positive
14 May 2024
(Supportive Care)
fhdahvdvxa(kthoknipyq) = ueusxhmfsm negchccluv (ihfcyfosbo )
Not Applicable
456
czcrmncetm(zruejedaen) = mvpplrzebv udenymxbam (ipwvsskooi )
Positive
14 May 2024
czcrmncetm(zruejedaen) = hmdgayatfj udenymxbam (ipwvsskooi )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free